PACB241220P500
- 0.00
- 0.000.00%
Pacific Biosciences of California Newsroom
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
ARKK's Holdings Ranked by SA Quant Grades
Pacific Biosciences of California | 10-Q: Q3 2024 Earnings Report
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Pacific Biosciences Price Target Announced at $2.00/Share by UBS
Express News | Pacific Biosciences of California Inc : UBS Cuts to Neutral From Buy
Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $6
Pacific Biosciences Is Maintained at Neutral by Piper Sandler
Pacific Biosciences Analyst Ratings
Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2.5
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
PacBio to Present at Upcoming Investor Conferences
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $4
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript Summary
Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates
Pacific Biosciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.